The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: A view of the Group for the Respect of Ethics and Excellence in Science (GREES)

Osteoporosis International

Volumn 21, Issue 5, 2010, Pages 713-722

  Bruyere, O ^a   Kanis, J A ^b   Ibar Abadie, M E ^c   Alsayed, N ^d   Brandi, M L ^e   Burlet, N ^f   Cahall, D L ^g   Chines, A ^h   Devogelaer, J P ⁱ   Dere, W ^j   Goel, N ^k   Hughes, N ^j   Kaufman, J M ^l   Korte, S ^m   Mitlak, B H ⁿ   Niese, D ^m   Rizzoli, R ^o   Rovati, L C ^p   Reginster, J Y ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c Lawyer Office   (France)

^d SANOFI PASTEUR   (France)

^e UNIVERSITY OF FLORENCE   (Italy)

^f International Osteoporosis Foundation Switzerland   (Switzerland)

^g SANOFI   (France)

^h PFIZER INC   (United States)

ⁱ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^j AMGEN INC   (United States)

^k UCB PHARMA   (Belgium)

^l GHENT UNIVERSITY HOSPITAL   (Belgium)

^m NOVARTIS PHARMA AG   (Switzerland)

ⁿ ELI LILLY AND COMPANY   (United States)

^o GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^p Rotta Research Laboratorium   (Italy)

more..

Author keywords

Competing interest; Conflict of interest; Ethics; Ghost authorship; Medical education

Indexed keywords

ARTICLE; CAREER MOBILITY; CONFLICT OF INTEREST; DRUG INDUSTRY; FUNDING; LAW; MEDICAL EDUCATION; MEDICAL ETHICS; MEDICAL RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; PUBLISHING; RESEARCH ETHICS; STAFF TRAINING;

AUTHORSHIP; CONFLICT OF INTEREST; DISCLOSURE; DRUG INDUSTRY; EDUCATION, MEDICAL; ETHICS, RESEARCH; HUMANS; INTERINSTITUTIONAL RELATIONS; SCHOOLS, MEDICAL; TRUST;

EID: 77951218934     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1190-9     Document Type: Article

References (64)

1. K Walsh J Sandars 2008 Competing interests and research in medical education Postgrad Med J 84 113 114 10.1136/pgmj.2007.066548 18372480 (Pubitemid 351498006)
2. IE Haines IN Olver 2008 Are self-regulation and declaration of conflict of interest still the benchmark for relationships between physicians and industry? Med J Aust 189 263 266 18759722
3. S Shaldon 2008 Conflict of interest in clinical guidelines should be avoided Nephrol Dial Transplant 23 1771 10.1093/ndt/gfm920 18187498 author reply 1772 (Pubitemid 351767772)
4. KC Elliott 2008 Scientific judgment and the limits of conflict-of-interest policies Account Res 15 1 29 18298027
5. S Sismondo 2008 How pharmaceutical industry funding affects trial outcomes: causal structures and responses Soc Sci Med 66 1909 1914 10.1016/j.socscimed.2008.01.010 18299169 (Pubitemid 351454041)
6. M Doucet S Sismondo 2008 Evaluating solutions to sponsorship bias J Med Ethics 34 627 630 10.1136/jme.2007.022467 1:STN:280:DC%2BD1cvoslCnsw%3D%3D 18667655
7. BA Chabner 2008 Conflict of interest: in the eye of the beholder? Oncologist 13 212 213 10.1634/theoncologist.2008-0041 18378530 (Pubitemid 351679895)
8. M Camilleri DA Cortese 2007 Managing conflict of interest in clinical practice Mayo Clin Proc 82 607 614 10.4065/82.5.607 17493426 (Pubitemid 46709429)
9. T Tungaraza R Poole 2007 Influence of drug company authorship and sponsorship on drug trial outcomes Br J Psychiatry 191 82 83 10.1192/bjp.bp.106.024547 17602130 (Pubitemid 47035186)
10. DG Duvall 2006 Conflict of interest or ideological divide: the need for ongoing collaboration between physicians and industry Curr Med Res Opin 22 1807 1812 10.1185/030079906X120977 16968584 (Pubitemid 44449237)
11. KP Weinfurt JY Friedman MA Dinan JS Allsbrook MA Hall JK Dhillon J Sugarman 2006 Disclosing conflicts of interest in clinical research: views of institutional review boards, conflict of interest committees, and investigators J Law Med Ethics 34 581-591 481 (Pubitemid 44505518)
12. JE Bekelman Y Li CP Gross 2003 Scope and impact of financial conflicts of interest in biomedical research: a systematic review JAMA 289 454 465 10.1001/jama.289.4.454 12533125 (Pubitemid 36119966)
13. Shaywitz D, Stossel T (2009) It's time to fight the " PharmaScolds". In Wall Street Journal
14. J Collier 2009 Doctors, patients, and the pharmaceutical industry BMJ 338 b443 10.1136/bmj.b443 19193618
15. Royal-College-of-Physicians (2009) Innovating for health: patient, physicians, the pharmaceutical industry and the NHS. Report of a Working Party, London
16. DJ Rothman WJ McDonald CD Berkowitz SC Chimonas CD DeAngelis RW Hale SE Nissen JE Osborn JH Scully Jr GE Thomson D Wofsy 2009 Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest JAMA 301 1367 1372 10.1001/jama.2009.407 1:CAS:528:DC%2BD1MXktFWisL8%3D 19336712
17. JA Christensen JP Orlowski 2005 Bounty-hunting and finder's fees IRB 27 16 19 10.2307/3564076 16021797
18. H Moses 3rd ER Dorsey DH Matheson SO Thier 2005 Financial anatomy of biomedical research JAMA 294 1333 1342 10.1001/jama.294.11.1333 1:CAS:528:DC%2BD2MXhtVeltr7F 16174691 (Pubitemid 41345812)
19. J Olesen I Lekander P Andlin-Sobocki B Jonsson 2007 Funding of headache research in Europe Cephalalgia 27 995 999 10.1111/j.1468-2982.2007.01397.x 1:STN:280:DC%2BD2srgvVegtw%3D%3D 17727472 (Pubitemid 47296033)
20. L Philipson 2005 Medical research activities, funding, and creativity in Europe: comparison with research in the United States JAMA 294 1394 1398 10.1001/jama.294.11.1394 1:CAS:528:DC%2BD2MXhtVeltrnO 16174700 (Pubitemid 41345821)
21. J Demotes-Mainard E Canet L Segard 2006 Public-private partnership models in France and in Europe Therapie 61 325-334 313 323 (Pubitemid 350188072)
22. H Moses 3rd E Braunwald JB Martin SO Thier 2002 Collaborating with industry-choices for the academic medical center N Engl J Med 347 1371 1375 10.1056/NEJMsb021319 12397200 (Pubitemid 35215333)
23. LA Bero S Glantz MK Hong 2005 The limits of competing interest disclosures Tob Control 14 118 126 1:STN:280:DC%2BD2M7lvVOkuw%3D%3D 15791022 (Pubitemid 40522560)
24. S Sismondo 2008 Pharmaceutical company funding and its consequences: a qualitative systematic review Contemp Clin Trials 29 109 113 10.1016/j.cct.2007.08.001 17919992 (Pubitemid 351248768)
25. JR Niebyl 2008 The pharmaceutical industry: friend or foe? Am J Obstet Gynecol 198 435 439 10.1016/j.ajog.2007.11.055 18395035 (Pubitemid 351451933)
26. J Haas 2008 Commentary: epidemiology and the pharmaceutical industry: an inside perspective Int J Epidemiol 37 53 55 10.1093/ije/dym264 18184672 discussion 65-58 (Pubitemid 351228610)
27. EA Boyd LA Bero 2007 Defining financial conflicts and managing research relationships: an analysis of university conflict of interest committee decisions Sci Eng Ethics 13 415 435 10.1007/s11948-007-9041-6 18008185
28. S Sismondo 2007 Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Med 4 e286 10.1371/journal.pmed.0040286 17896859 (Pubitemid 47503031)
29. JY Reginster 2007 The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest Arthritis Rheum 56 2105 2110 10.1002/art.22852 1:CAS:528:DC%2BD2sXovFSgsLk%3D 17599727 (Pubitemid 47173556)
30. Pharmaceutical Research and Manufacturers of America (PhRMA) (2008) Code on interactions with healthcare professionals
31. E Wager EA Field L Grossman 2003 Good publication practice for pharmaceutical companies Curr Med Res Opin 19 149 154 10.1185/030079903125001767 12814125 (Pubitemid 36612997)
32. KA Schulman DM Seils JW Timbie J Sugarman LA Dame KP Weinfurt DB Mark RM Califf 2002 A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors N Engl J Med 347 1335 1341 10.1056/NEJMsa020349 12397192 (Pubitemid 35215325)
33. P Campbell 2001 Declaration of financial interests Nature 412 751 10.1038/35090688 1:STN:280:DC%2BD3MvnsFCktw%3D%3D 11518924 (Pubitemid 32801428)
34. E Wager 2004 The need for trial identifiers Curr Med Res Opin 20 203 206 10.1185/030079903125002883 15006015 (Pubitemid 38202183)
35. L Hirsch 2008 Trial registration and results disclosure: impact of US legislation on sponsors, investigators, and medical journal editors Curr Med Res Opin 24 1683 1689 10.1185/03007990802114849 18462565 (Pubitemid 351929066)
36. J Goldhahn B Mitlak P Aspenberg JA Kanis R Rizzoli JY Reginster 2008 Critical issues in translational and clinical research for the study of new technologies to enhance bone repair J Bone Jt Surg Am 90 Suppl 1 43 47 10.2106/JBJS.G.01090 (Pubitemid 351329120)
37. J Compston DM Reid J Boisdron ML Brandi N Burlet D Cahall PD Delmas W Dere JP Devogelaer LA Fitzpatrick B Flamion N Goel S Korte A Laslop B Mitlak S Ormarsdottir J Ringe R Rizzoli Y Tsouderos T Van Staa JY Reginster 2008 Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science Osteoporos Int 19 1247 1250 10.1007/s00198-008-0670-7 1:STN:280:DC%2BD1crhtVyrsw%3D%3D 18604578
38. F Lekkerkerker JA Kanis N Alsayed G Bouvenot N Burlet D Cahall A Chines P Delmas RL Dreiser D Ethgen N Hughes JM Kaufman S Korte G Kreutz A Laslop B Mitlak V Rabenda R Rizzoli A Santora R Schimmer Y Tsouderos P Viethel JY Reginster 2007 Adherence to treatment of osteoporosis: a need for study Osteoporos Int 18 1311 1317 10.1007/s00198-007-0410-4 1:STN:280: DC%2BD2srjtVensw%3D%3D 17585359 (Pubitemid 47389473)
39. JY Reginster E Abadie P Delmas R Rizzoli W Dere P der Auwera B Avouac ML Brandi A Daifotis A Diez-Perez G Calvo O Johnell JM Kaufman G Kreutz A Laslop F Lekkerkerker B Mitlak P Nilsson J Orloff M Smillie A Taylor Y Tsouderos D Ethgen B Flamion 2006 Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men Osteoporos Int 17 1 7 10.1007/s00198-005-1984-3 16091835 (Pubitemid 41798022)
40. E Abadie D Ethgen B Avouac G Bouvenot J Branco O Bruyere G Calvo JP Devogelaer RL Dreiser G Herrero-Beaumont A Kahan G Kreutz A Laslop EM Lemmel G Nuki L Van De Putte L Vanhaelst JY Reginster 2004 Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis Osteoarthritis Cartilage 12 263 268 10.1016/j.joca.2004.01.006 15023377 (Pubitemid 38461288)
41. ST Holgate J Bousquet KF Chung H Bisgaard R Pauwels L Fabbri K Rabe M Doherty NJ Snell F Cuss M D'Amato JY Reginster 2004 Summary of recommendations for the design of clinical trials and the registration of drugs used in the treatment of asthma Respir Med 98 479 487 10.1016/j.rmed.2003.12.005 1:STN:280:DC%2BD2c3ptVWisg%3D%3D 15191031 (Pubitemid 38701850)
42. PD Delmas G Calvo M Boers E Abadie B Avouac A Kahan JM Kaufman A Laslop JF Lekkerkerker P Nilsson B Van Zwieten-Boot G Kreutz JY Reginster 2002 The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis Osteoporos Int 13 1 5 10.1007/s198-002-8331-3 1:STN:280:DC%2BD387ksVGmtw%3D%3D 11878450 (Pubitemid 34157825)
43. E Vignon P Garnero P Delmas B Avouac P Bettica M Boers E Ehrich N MacKillop L Rovati U Serni T Spector JY Reginster 2001 Recommendations for the registration of drugs used in the treatment of osteoarthritis: an update on biochemical markers Osteoarthritis Cartilage 9 289 293 10.1053/joca.2000.0387 1:STN:280:DC%2BD3MzjsVKlsA%3D%3D 11403034 (Pubitemid 32454771)
44. Group for the Respect of Ethics and Excellence in Science (GREES) 1998 Recommendations for the registration of drugs used in the treatment of rheumatoid arthritis: rheumatoid arthritis section Br J Rheumatol 37 211 215 10.1093/rheumatology/37.2.211 (Pubitemid 128693287)
45. JA Kanis O Johnell A Oden H Johansson C De Laet JA Eisman S Fujiwara H Kroger EV McCloskey D Mellstrom LJ Melton H Pols J Reeve A Silman A Tenenhouse 2005 Smoking and fracture risk: a meta-analysis Osteoporos Int 16 155 162 10.1007/s00198-004-1640-3 1:STN:280:DC%2BD2M%2FksVentA%3D%3D 15175845 (Pubitemid 40193202)
46. DF Horrobin 1999 Beyond conflict of interest. Non-financial conflicts of interest are more serious than financial conflicts BMJ 318 466 1:STN:280:DyaK1M7otFOhsA%3D%3D 10084844
47. The PLoS Medicine Editors 2008 Making sense of non-financial competing interests PLoS Med 5 e199 10.1371/journal.pmed.0050199
48. L Bero 2008 "Experimental" institutional models for corporate funding of academic research: unknown effects on the research enterprise J Clin Epidemiol 61 629 633 10.1016/j.jclinepi.2008.01.002 18538259 (Pubitemid 351760977)
49. ER de Haas HC de Vijlder WS van Reesema JJ van Everdingen HA Neumann 2007 Quality of clinical practice guidelines in dermatological oncology J Eur Acad Dermatol Venereol 21 1193 1198 17894704 (Pubitemid 47423406)
50. DA Reed DA Cook TJ Beckman RB Levine DE Kern SM Wright 2007 Association between funding and quality of published medical education research JAMA 298 1002 1009 10.1001/jama.298.9.1002 1:CAS:528:DC%2BD2sXhtVaisLzI 17785645 (Pubitemid 47360811)
51. J Lexchin LA Bero B Djulbegovic O Clark 2003 Pharmaceutical industry sponsorship and research outcome and quality: systematic review BMJ 326 1167 1170 10.1136/bmj.326.7400.1167 12775614 (Pubitemid 36649048)
52. M Angell JP Kassirer 1996 Editorials and conflicts of interest N Engl J Med 335 1055 1056 10.1056/NEJM199610033351410 1:STN:280:DyaK28zmvFGqtg%3D%3D 8793932 (Pubitemid 26338738)
53. JM Drazen GD Curfman 2002 Financial associations of authors N Engl J Med 346 1901 1902 10.1056/NEJMe020074 12063375 (Pubitemid 34603034)
54. JS Ancker A Flanagin 2007 A comparison of conflict of interest policies at peer-reviewed journals in different scientific disciplines Sci Eng Ethics 13 147 157 10.1007/s11948-007-9011-z 17717729
55. S Chaudhry S Schroter R Smith J Morris 2002 Does declaration of competing interests affect readers' perceptions? A randomised trial BMJ 325 1391 1392 10.1136/bmj.325.7377.1391 12480854 (Pubitemid 35477844)
56. D Healy D Cattell 2003 Interface between authorship, industry and science in the domain of therapeutics Br J Psychiatry 183 22 27 10.1192/bjp.183.1.22 12835239 (Pubitemid 36831259)
57. M McLennan FC Leong A Steele J Harris 2008 The influence of industry sponsorship on the acceptance of abstracts and their publication Am J Obstet Gynecol 198 579 e571 e574 (Pubitemid 351608996)
58. F Davidoff CD DeAngelis JM Drazen J Hoey L Hojgaard R Horton S Kotzin MG Nicholls M Nylenna AJ Overbeke HC Sox MB Van Der Weyden MS Wilkes 2001 Sponsorship, authorship, and accountability Lancet 358 854 856 10.1016/S0140-6736(01)06035-4 1:STN:280:DC%2BD3Mrit1eitg%3D%3D 11567695 (Pubitemid 32900562)
59. T Bodenheimer 2000 Uneasy alliance-clinical investigators and the pharmaceutical industry N Engl J Med 342 1539 1544 10.1056/NEJM200005183422024 1:STN:280:DC%2BD3c3ls1Ohug%3D%3D 10816196 (Pubitemid 30318291)
60. International Committee of Medical Journal Editors 1997 Uniform requirements for manuscripts submitted to biomedical journals JAMA 277 927 934 10.1001/jama.277.11.927 (Pubitemid 27123956)
61. C Graf WP Battisti D Bridges V Bruce-Winkler JM Conaty JM Ellison EA Field JA Gurr ME Marx M Patel C Sanes-Miller YE Yarker 2009 Good publication practice for communicating company sponsored medical research: the GPP2 guidelines BMJ 339 b4330 10.1136/bmj.b4330 19946142
62. A Jacobs E Wager 2005 European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications Curr Med Res Opin 21 317 322 10.1185/030079905X25578 15802003 (Pubitemid 40469909)
63. R Norris A Bowman JM Fagan ER Gallagher AB Geraci A Gertel L Hirsch PD Ross TP Stossel K Veitch D Woods 2007 International Society for Medical Publication Professionals (ISMPP) position statement: the role of the professional medical writer Curr Med Res Opin 23 1837 1840 10.1185/ 030079907X210642 17605897 (Pubitemid 47300382)
64. D Moher KF Schulz D Altman 2001 The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials JAMA 285 1987 1991 10.1001/jama.285.15.1987 1:STN:280:DC%2BD3M3kvFagug%3D%3D 11308435 (Pubitemid 32366951)